| Medical and Health Sciences | 2021-2025 | 683 | JP 7 | 99.85 |
| Infectious Diseases | Lifetime | 534 | JP 3 | 97.91 |
| Applied Microbiology and Biotechnology | Lifetime | 58 | JP 2 | 96.37 |
| Molecular Medicine | Lifetime | 393 | JP 13 | 87.99 |
| Modeling and Simulation | Lifetime | 515 | JP 14 | 81.04 |
| Clinical Biochemistry | Lifetime | 811 | JP 23 | 78.21 |
| Parasitology | Lifetime | 835 | JP 16 | 64.46 |
| Infectious Diseases | 2021-2025 | 34 | JP 1 | 99.55 |
| Applied Microbiology and Biotechnology | 2021-2025 | 14 | JP 1 | 96.99 |
| Clinical Neurology | 2021-2025 | 138 | JP 3 | 96.67 |
| Epidemiology | 2021-2025 | 431 | JP 11 | 96.25 |
| Clinical Biochemistry | 2021-2025 | 44 | JP 2 | 87.82 |
| Clinical Psychology | 2021-2025 | 987 | JP 7 | 88.31 |
| Modeling and Simulation | 2021-2025 | 230 | JP 4 | 86.74 |
| Virology | 2021-2025 | 110 | JP 1 | 80.63 |
| Molecular Medicine | 2021-2025 | 162 | JP 6 | 71.03 |
| COVID-19 Clinical Research Studies | Lifetime | 192 | JP 2 | 99.04 |
| Long-Term Effects of COVID-19 | Lifetime | 115 | JP 1 | 98.71 |
| SARS-CoV-2 and COVID-19 Research | Lifetime | 336 | JP 6 | 98.76 |
| Antibiotic Use and Resistance | Lifetime | 222 | JP 3 | 98.44 |
| COVID-19 and healthcare impacts | Lifetime | 388 | JP 6 | 95.32 |
| SARS-CoV-2 detection and testing | Lifetime | 215 | JP 11 | 96.06 |
| COVID-19 and Mental Health | Lifetime | 766 | JP 6 | 95.19 |
| Enterobacteriaceae and Cronobacter Research | Lifetime | 585 | JP 23 | 87.94 |
| Travel-related health issues | Lifetime | 470 | JP 5 | 87.10 |
| COVID-19 Clinical Research Studies | 2021-2025 | 35 | JP 1 | 99.71 |
| Long-Term Effects of COVID-19 | 2021-2025 | 28 | JP 1 | 99.39 |
| SARS-CoV-2 and COVID-19 Research | 2021-2025 | 96 | JP 1 | 99.50 |
| Antibiotic Use and Resistance | 2021-2025 | 42 | JP 1 | 98.50 |
| COVID-19 and healthcare impacts | 2021-2025 | 188 | JP 6 | 96.18 |
| SARS-CoV-2 detection and testing | 2021-2025 | 107 | JP 6 | 97.10 |
| Bacterial Identification and Susceptibility Testing | 2021-2025 | 87 | JP 3 | 96.58 |
| COVID-19 and Mental Health | 2021-2025 | 447 | JP 5 | 96.03 |
| Streptococcal Infections and Treatments | 2021-2025 | 144 | JP 2 | 92.53 |
| Urinary Tract Infections Management | 2021-2025 | 169 | JP 6 | 92.04 |
| Bacillus and Francisella bacterial research | 2021-2025 | 109 | JP 1 | 91.02 |
| Antibiotic Resistance in Bacteria | 2021-2025 | 695 | JP 13 | 93.16 |
| COVID-19 epidemiological studies | 2021-2025 | 735 | JP 13 | 92.08 |
| Poxvirus research and outbreaks | 2021-2025 | 166 | JP 2 | 88.46 |
| Antimicrobial Resistance in Staphylococcus | 2021-2025 | 378 | JP 12 | 88.84 |
| Herpesvirus Infections and Treatments | 2021-2025 | 566 | JP 12 | 83.36 |
| COVID-19 Impact on Reproduction | 2021-2025 | 872 | JP 9 | 81.96 |
| Neutropenia and Cancer Infections | 2021-2025 | 568 | JP 27 | 75.38 |
| Data-Driven Disease Surveillance | 2021-2025 | 353 | JP 12 | 75.46 |
| Patient Satisfaction in Healthcare | 2021-2025 | 639 | JP 4 | 75.75 |
| Virology and Viral Diseases | 2021-2025 | 586 | JP 18 | 74.60 |
| Travel-related health issues | 2021-2025 | 160 | JP 3 | 74.02 |
| Nosocomial Infections in ICU | 2021-2025 | 953 | JP 47 | 67.26 |
| Enterobacteriaceae and Cronobacter Research | 2021-2025 | 703 | JP 46 | 40.71 |
| Infections and bacterial resistance | 2021-2025 | 715 | JP 52 | 29.82 |